
Molly Silkowski, DO
@mollysilkowski
•Advanced Heart Failure/Transplant Fellow @MUSC •Upcoming Interventional Cardiology fellow. •Interested in all things Shock and dogs.
ID: 1168495987419156481
02-09-2019 12:09:03
169 Tweet
520 Takipçi
443 Takip Edilen



In 2016, I watched my first coronary angiogram. Quinn Capers, IV took me to the cath lab after my The Ohio State University College of Medicine interview. 7 years and innumerable guidance and mentorship sessions later I'm joining him as interventional cardiology faculty at UTSW Media Relations Representation matters!



Former OSU fellow Jeremy Slivnick and current Akash Goyal on the author list for this paper on cardiac amyloid imaging. OhioStateDHLRI Gumina Lab Laurie Bossory Goike Lauren Hassen, MD MPH



Molly Silkowski, DO (Molly Silkowski, DO), and Anbukarasi Maran, MD (Arasi Maran), provide an up-to-date assessment of coronary perforation, including a look at balloon tamponade, thrombin, and multiple technological management tools. citoday.com/articles/2024-…


Congratulations Rahul G Argula and colleagues on this critical study. Sometimes doing nothing is better than doing something. Denise Sese Thenappan Thenappan Sam Friedman MUSC Health Molly Silkowski, DO MUSC Cardiology Fellowship Programs

🔥🚒 Pioneering the role of full-time, dedicated “temporary MCS coordinator” at MUSC Cardiology - VERY proud to be a part of this group!! ahajournals.org/doi/abs/10.116…

I am so glad MUSC Health did its first #AGENT DCB for ISR of Left Main. Congratulations Jeffrey Yourshaw, Mayank Patel Carson Keck ! --danny. Eric Powers BostonSci Cardiology Patrick M Looser MD Nitesh Ainani MUSC Cardiology Fellowship Programs MUSC-WomenInCardiology




Drs. Harshith Chandrakumar (Harshith Chandrakumar), Molly Silkowski (Molly Silkowski, DO), & Anbukarasi Maran (Arasi Maran), discuss calcific coronary lesion imaging & treatment, diving into the pros & cons of available imaging modalities & modification therapies. citoday.com/articles/2024-…


Sacubitril/Valsartan in patients with HF & deterioration in eGFR to <30 with therapy. Continuation of ARNi was associated with persistent clinical benefit and no incremental risk. JACC Journals #JACCHF jacc.org/doi/10.1016/j.…

